Cargando…
Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
Neovascularization facilitates tumour growth and metastasis formation. In our laboratory, we attempt to identify clinically available oral efficacious drugs for antiangiogenic activity. Here, we report which non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit corneal neovascularization, induc...
Autores principales: | Verheul, H M W, Panigrahy, D, Yuan, J, D'Amato, R J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362163/ https://www.ncbi.nlm.nih.gov/pubmed/10408702 http://dx.doi.org/10.1038/sj.bjc.6690020 |
Ejemplares similares
-
Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases
por: Benny, Ofra, et al.
Publicado: (2010) -
Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs
por: Peach, Megan L., et al.
Publicado: (2020) -
Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia
por: Ansari, Saqib H., et al.
Publicado: (2022) -
The treatment of advanced renal cell cancer with high-dose oral thalidomide
por: Stebbing, J, et al.
Publicado: (2001) -
Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats
por: Madka, Venkateshwar, et al.
Publicado: (2023)